Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity
Vaccines · 12.02.2024 · 12 (2) · 186
DOI: 10.3390/vaccines12020186 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 12.02.2024. Verfasst von Liusheng Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center of Hepatobiliary Pancreatic Disease, Beijing Tsinghua Changgung Hospital, School of Medicine, Tsinghua University, Beijing 100084, China. Die Arbeit wurde bisher 133-mal zitiert (Crossref) und nennt 268 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Scientific Research Foundation of Peking University Shenzhen Hospital, Research and Development of Intelligent Surgical Navigation and Operating System for Precise Liver Resection.
Abstract (Originalsprache)
In recent years, lipid nanoparticles (LNPs) have attracted extensive attention in tumor immunotherapy. Targeting immune cells in cancer therapy has become a strategy of great research interest. mRNA vaccines are a potential choice for tumor immunotherapy, due to their ability to directly encode antigen proteins and stimulate a strong immune response. However, the mode of delivery and lack of stability of mRNA are key issues limiting its application. LNPs are an excellent mRNA delivery carrier, and their structural stability and biocompatibility make them an effective means for delivering mRNA to specific targets. This study summarizes the research progress in LNP delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity. The role of LNPs in improving mRNA stability, immunogenicity, and targeting is discussed. This review aims to systematically summarize the latest research progress in LNP delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity to provide new ideas and strategies for tumor immunotherapy, as well as to provide more effective treatment plans for patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center of Hepatobiliary Pancreatic Disease, Beijing Tsinghua Changgung Hospital, School of Medicine, Tsinghua University, Beijing 100084, China.
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077, Singapore.
- Department of Thoracic Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, China.
ORCID-Profile: Liusheng Wu, Xiaoqiang Li
Förderung
- National Natural Science Foundation of China
- Scientific Research Foundation of Peking University Shenzhen Hospital
- Research and Development of Intelligent Surgical Navigation and Operating System for Precise Liver Resection
- Start-up Fund for Talent Researchers of Tsinghua University
- National Science and Technology Major Project of China
- 2018 Peking University-University of Michigan JI Project
- 2018 Shenzhen Science and Technology Innovation Gene Project
- 2020 Open Fund Project of the Shenzhen Huada School of Life Sciences
Zitieren
APA
Wu, L., Li, X., Qian, X., Wang, S., Liu, J., & Yan, J. (2024). Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines, 12(2), 186. https://doi.org/10.3390/vaccines12020186
Vancouver
Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines. 2024;12(2):186. doi:10.3390/vaccines12020186
BibTeX
@article{Wu2024,
author = {Wu, Liusheng and Li, Xiaoqiang and Qian, Xinye and Wang, Shuang and Liu, Jixian and Yan, Jun},
title = {Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity},
journal = {Vaccines},
year = {2024},
volume = {12},
number = {2},
pages = {186},
doi = {10.3390/vaccines12020186}
}
EUVIMED